文献速递肾移植

基于医保索赔数据对急性肾移植排斥反应进行表型分型:全国性Medicare队列研究

Claims-Based Phenotyping of Acute Kidney Transplant Rejection in a National Medicare Cohort.
PubMed 文献 · Kidney Int Rep · 2026-09-03

本研究利用美国肾脏数据系统(USRDS)2012-2021年92,845例成人肾移植受者数据,通过索赔算法识别移植后12个月内急性排斥反应(AR)并按治疗方案分型。共识别5,712次AR发作,其中轻度急性细胞性排斥(ACR)占69.4%、重度ACR占8.8%、抗体介导排斥(AMR)占19.7%、混合型占2.1%;在3,052次活检确认的发作中,3年死亡删失移植存活率在各表型间差异显著(轻度ACR 87.9%、重度ACR 80.7%、AMR 73.5%、混合型68.4%,P<0.05),校正后趋势持续。结论表明基于索赔数据的表型分型可在全国范围内识别有临床意义的AR亚型及预后梯度。

要点

  • 索赔算法可识别轻度ACR、重度ACR、AMR及混合型四种AR表型。
  • 活检确认的AR表型间3年死亡删失移植存活率存在显著梯度差异(P<0.05)。
  • 该表型分型方法支持全国范围内更细化的排斥监测。

核心结论

  • 基于索赔数据的表型分型可在全国尺度识别有临床意义的急性排斥亚型及预后梯度,支持更细化的全国排斥监测。

研究设计与样本

  • 队列研究,使用美国肾脏数据系统(USRDS)2012-2021年成人肾移植受者数据,共92,845例受者。

主要发现

  • 共识别5,712次AR发作:轻度ACR 69.4%、重度ACR 8.8%、AMR 19.7%、混合型(ACR+AMR)2.1%。
  • 在3,052次活检确认的发作中,3年死亡删失移植存活率分别为轻度ACR 87.9%、重度ACR 80.7%、AMR 73.5%、混合型68.4%(P<0.05)。
  • 校正受者及供者特征后,上述存活率趋势持续存在。

关键数值与推荐

  • AR定义为移植后12个月内使用移植并发症ICD编码且2周内有抗排斥治疗证据。
  • 根据治疗方案对发作进行类型和严重程度分类;活检相关AR定义为治疗前14天内行肾活检。

临床怎么用

  • 可利用索赔数据算法在全国层面识别AR表型并评估预后梯度,辅助排斥监测与风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: National transplant registries record acute rejection (AR) without the granularity needed to study rejection heterogeneity and prognosis at scale. Whether AR can be stratified by type and severity in national claims data using a claims-based algorithm, and whether these phenotypes correlate with graft outcomes, remains unclear. METHODS: We conducted a cohort study using the US Renal Data System (USRDS) data including adult kidney transplant recipients from 2012-2021. AR within 12 months posttransplant was identified using International Classification of Diseases codes for transplant complications with evidence of antirejection treatment within 2 weeks. Episodes were categorized by type and severity based on treatment regimen. Biopsy-associated AR was defined by renal biopsy within 14 days before the treatment. Death-censored graft survival was assessed using Kaplan-Meier methods and multivariable Cox proportional hazards models. RESULTS: Among 92,845 recipients, 5712 AR episodes were identified (69.4% mild acute-cellular rejection [ACR], 8.8% severe ACR, 19.7% antibody-mediated rejection [AMR], and 2.1% mixed [ACR + AMR]). Among 3052 biopsy-confirmed episodes, 3-year death-censored graft survival differed meaningfully across phenotypes (87.9% mild ACR, 80.7% severe ACR, 73.5% AMR, and 68.4% mixed [ACR + AMR] [P < 0.05]), with trends persisting after adjustment for recipient and donor characteristics. CONCLUSION: Claims-based phenotyping can identify clinically meaningful AR subtypes and prognostic gradients at national scale, enabling more granular national rejection surveillance.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ekanayake C, Yu M, Natarajan K, et al. Claims-Based Phenotyping of Acute Kidney Transplant Rejection in a National Medicare Cohort. Kidney Int Rep. 2026. PMID: 42898365. doi:10.1016/j.ekir.2026.107060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。